Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ChAdOx1-HPV · 1 trial · 2 indications
Measure of adverse events, serious adverse events (SAEs), ≥Grade 3 study vaccine-related adverse events reported.
| Arm | Type | Description |
|---|---|---|
| Lead-in Group A ChAdOx1-HPV low dose and MVA-HPV low dose | EXPERIMENTAL | Prime-boost vaccine doses: ChAdOx1-HPV (2 x 10\^8 vp) and MVA-HPV (1 x 10\^7 pfu) |
| Lead-in Group B ChAdOx1-HPV mid dose and MVA-HPV low dose | EXPERIMENTAL | Prime-boost vaccine doses: ChAdOx1-HPV (2 x 10\^9 vp) and MVA-HPV (1 x 10\^7 pfu) |
| Lead-in Group C ChAdOx1-HPV high dose and MVA-HPV high dose | EXPERIMENTAL | Prime-boost vaccine doses: ChAdOx1-HPV (2 x 10\^10) vp and MVA-HPV (1 x 10\^8 pfu) |
| Group 1 ChAdOx1-HPV mid dose and MVA-HPV low dose | EXPERIMENTAL | Prime-boost vaccine doses: ChAdOx1-HPV (2 x 10\^9 vp) and MVA-HPV (1 x 10\^7 pfu) |
| Group 2 ChAdOx1-HPV high dose and MVA-HPV low dose | EXPERIMENTAL | Prime-boost vaccine doses: ChAdOx1-HPV (2 x 10\^10 vp) and MVA-HPV (1 x 10\^7 pfu) |
| Group 3 ChAdOx1-HPV low dose and MVA-HPV high dose | EXPERIMENTAL | Prime-boost vaccine doses: ChAdOx1-HPV (2 x 10\^8 vp) and MVA-HPV (1 x 10\^8 pfu) |
| Group 4 ChAdOx1-HPV mid dose and MVA-HPV high dose | EXPERIMENTAL | Prime-boost vaccine doses: ChAdOx1-HPV (2 x 10\^9 vp) and MVA-HPV (1 x 10\^8 pfu) |
| Group 5 ChAdOx1-HPV high dose and MVA-HPV high dose | EXPERIMENTAL | Prime-boost vaccine doses: ChAdOx1-HPV (2 x 10\^10 vp) and MVA-HPV (1 x 10\^8 pfu) |
| Group 6 Placebo Saline | PLACEBO_COMPARATOR | Sodium Chloride (0.9%) |
| Name | Type | Description |
|---|---|---|
| ChAdOx1-HPV | BIOLOGICAL | Trial vaccine |
| MVA-HPV | BIOLOGICAL | Trial vaccine |
| Placebo | BIOLOGICAL | Saline placebo vaccine |
Inclusion Criteria: 1. Females aged ≥25 and ≤55 years of age at screening. 2. Persistent hrHPV infection defined as a documented cervical infection with hrHPV type(s) in the 6 to 18 months prior to screening and confirmed at screening (participants in the main and expansion phases only). Participan...
Top 19 of 30 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Pfizer Inc. | PFE | 7 | PHASE3 | VLA15, Prevenar 20, 13vPnC, ATM-AVI, PG4 |
| Sanofi SA Sponsored ADR | SNY | 1 | PHASE3 | PCV21 |
| GSK plc Sponsored ADR | GSK | 4 | PHASE2 | Penmenvy, iNTS-TCV, Strep A vaccine, Pan-Salmonella vaccine |
| Grifols, S.A. Sponsored ADR Class B | GRFS | 1 | PHASE3 | Xembify |
| CorMedix Inc. | CRMD | 1 | PHASE3 | DefenCath |
| Sinovac Biotech Ltd. | SVA | 4 | PHASE3 | Sinovac PCV24, Group ACYW135X Meningococcal Conjugate Vaccine, Group ACYW135 Meningococcal Conjugate Vaccine |
| Novartis AG Sponsored ADR | NVS | 2 | PHASE2 | EDI048 |
| Innoviva, Inc. | INVA | 3 | PHASE2 | Eravacycline, Sulbactam-durlobactam |
| BiomX Inc. | PHGE | 1 | PHASE2 | BX004 |
| Hoffmann-La Roche | RHHBY | 1 | PHASE3 | Baloxavir Marboxil |
| Merck & Co., Inc. | MRK | 2 | PHASE1 | V118C |
| AstraZeneca PLC | AZN | 1 | PHASE1 | AZD7760 |
| BioNTech SE Sponsored ADR | BNTX | 1 | PHASE1 | BNT163 |
| 60 Degrees Pharmaceuticals, Inc. | SXTP | 1 | PHASE2 | Tafenoquine |
| Tarsus Pharmaceuticals, Inc. | TARS | 1 | PHASE2 | TP-05 |
| Moderna, Inc. | MRNA | 1 | PHASE2 | mRNA-1982 |
| AN2 Therapeutics, Inc. | ANTX | 1 | PHASE2 | Epetraborole |
| Emergent BioSolutions Inc. | EBS | 4 | - | AIGIV/kg |
| Phathom Pharmaceuticals, Inc. | PHAT | 1 | - | Vonoprazan |
ChAdOx1-HPV is an investigational vaccine being studied for the treatment of HPV infection, specifically in women with low-grade cervical HPV lesions (CIN1). It is in Phase 1 clinical development and is not yet approved by regulatory authorities.
ChAdOx1-HPV is a vaccine designed to target HPV infection. It is being evaluated in women with low-grade cervical HPV lesions (CIN1) to assess its ability to generate an immune response against the virus.
ChAdOx1-HPV is being developed by Barinthus Biotherapeutics plc, a biopharmaceutical company listed on the stock exchange under the ticker symbol BRNS.
ChAdOx1-HPV is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. One Phase 1 trial has been completed.
ChAdOx1-HPV has been studied in one completed Phase 1 clinical trial, NCT04607850, titled 'Prime-boost Vaccine Study in Women With Low-grade Cervical HPV Lesions.' The trial enrolled 108 women aged 25 years and older with HPV infection and CIN1 in Belgium, Estonia, and the United Kingdom.
No, ChAdOx1-HPV is a vaccine, not a monoclonal antibody. It is being developed to treat HPV infection by stimulating the immune system, rather than by directly targeting the virus with antibodies.